is no difference between groups—and test it using statistical data.

Type I Error (α):

Rejecting the null hypothesis when it is actually true — also known as a “false positive.”

• Common alpha levels: 0.05 (5%) or 0.01 (1%)
• Meaning: A 5% chance of concluding there is a difference when there isn’t

Type II Error (β):

Failing to reject the null hypothesis when it is false — also known as a “false negative.”

• Common beta: 0.2 (20%) → Power = 1 – β = 80%
• Meaning: A 20% chance of missing a real difference

What Is Statistical Power?

Power is the probability of correctly rejecting a false null hypothesis. In simpler terms, it measures the ability of a trial to detect a real effect when it exists.

• Higher power = lower chance of Type II error
• Typically set at 80% or 90%
• Depends on: effect size, sample size, alpha, and variability

Relationship Between Power, Effect Size, and Errors

These elements are interrelated. To increase power, you can:

• Increase the effect size (if realistic)
• Increase the sample size
• Accept a higher alpha (not recommended)
• Reduce data variability through better design or control

For example, in stability testing protocols, reducing variability through precise environmental control helps improve detection sensitivity—analogous to increasing power.

Visualizing the Concepts

Imagine two overlapping bell curves—one for the null hypothesis and one for the alternative. The degree of overlap reflects the likelihood of errors:

• High overlap = high risk of Type I and II errors
• Greater effect size = curves shift apart = easier to detect differences

Examples from Clinical Trials

Example 1: Antihypertensive Study

Goal: Detect an 8 mmHg difference in systolic BP between treatment and placebo. Assuming SD of 15, α = 0.05, and power = 90%:

• Effect size = 8 / 15 = 0.53 (moderate)
• Sample size per arm ≈ 86 (calculated using software)

Example 2: Oncology Trial

Goal: Detect Hazard Ratio (HR) of 0.7 with median survival of 12 vs 17 months. Alpha = 0.05, power = 80%:

• Use log-rank test formulas
• Required number of events ≈ 180
• Adjust for dropout to determine final N

Common Mistakes and Misconceptions

• ❌ Setting α = 0.01 without adjusting sample size accordingly
• ❌ Assuming large effect size to reduce sample size without justification
• ❌ Confusing power with significance level
• ❌ Not accounting for dropout in power analysis
• ❌ Using underpowered studies that risk inconclusive results

Regulatory Expectations

According to pharma regulatory requirements and GCP guidelines, protocols must:

• Clearly define primary endpoints and corresponding hypotheses
• Justify chosen alpha and power levels
• Document all assumptions used for sample size estimation
• Include rationale for clinically relevant effect sizes

Missing or poorly justified statistical parameters often lead to queries from regulators or rejection of clinical data.

Best Practices for Statistical Planning

1. Collaborate Early: Involve biostatisticians during protocol drafting
2. Use Pilot or Literature Data: For realistic effect size estimates
3. Document Everything: In protocol and SAP for traceability
4. Apply Sensitivity Analysis: For robustness across assumptions
5. Validate with QA: As part of pharma SOP documentation

Conclusion: Clarity in Statistical Assumptions Builds Confidence

Effect size, statistical power, and Type I/II errors are the cornerstones of meaningful trial design. Understanding these terms not only improves study robustness but also facilitates communication with regulators and clinical stakeholders. By applying rigorous statistical planning, sponsors ensure ethical, efficient, and successful clinical trials.

Explore More:

• GMP training
• Process validation